Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 1, 1997, Pages 26-31

  Byrnes, C A ^a   Liss, C L ^a   Tenover, J L ^b   Lippert, M C ^c   Gillenwater, J Y ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

BPH; Finasteride; Prostate

Indexed keywords

EID: 0344791454     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500202     Document Type: Article

References (21)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-478.
2. Girman CJ et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825-831.
3. Imperato-McGinley J, Peterson RE, Gautier T, Sturla A. Male pseudohermaphroditism secondary to 5-alpha reductase definciency: a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem 1979; 11: 637-645.
4. Fratianni CM, Imperato-McGinley J. The syndrome of 5-alpha reductase deficiency. Endocrinologist 1994; 4: 302-314.
5. Gormley GJ et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-1191.
6. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-299.
7. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284-294.
8. Lepor H, Stoner E. Long-term results of medical therapies for benign prostatic hyperplasia. Curr Opin Urol 1995; 5: 18-24.
9. Moore E et al. Proscar©: Five-year experience.. Eur Urol 1995; 28(4): 304-309.
10. Boyle P, Gould L, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405.
11. Byrnes CA et al. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community-based study. Clin Therap 1995; 17: 956-969.
12. Tenover JL et al. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: A primary care study. Clin Therap 1997; 19 (2): 243-258
13. Barry MJ et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-1557.
14. Barry MJ et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33: AS145-AS155.
15. Roehrborn CG et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasonography. Urology 1997; 49: 548-557.
16. Arocho R, Kason NM, Colón B, McMillan CA. Translation and validation of the American Urological Association Symptom Index into Spanish. Clin Therap 1995; 17 (4): 777-785.
17. Statistical abstract of the United States 1994. Washington DC: US Department of Commerce. Economics and Statistics Administration, Bureau of the Census. 1994; 114: 17-18.
18. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31-37.
19. Guess HA et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am 1993; 20: 627-636.
20. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155: 3-9.
21. Prescribing information for Proscar© (Finasteride), Merck and Co., Inc., West Point, PA., 1995.